Spironolactone Misses the Mark in Acute MI Without HF

(MedPage Today) -- CHICAGO -- A mineralocorticoid receptor antagonist (MRA) was unable to further improve 3-year outcomes of acute myocardial infarction (MI) in the modern era, based on the CLEAR OASIS 9 trial.
Among heart attack survivors without...